organization · Reporting owner
PureTech Health plc
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GELESIS HOLDINGS, INC.GLSH · Entity 109516 | 10% owner | September 20, 2023 | September 21, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GELESIS HOLDINGS, INC.
Report date September 20, 2023 · Filed September 21, 2023
Jointly reported with PureTech Health LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2024-03-31 | IndirectBy PureTech Health LLC | Not disclosed |
Reported balance
After 2023-09-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-09-20 · Purchase · Acquired Not disclosed · Balance Not disclosed |
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akili, Inc.
Report date July 02, 2024 · Filed July 08, 2024
Jointly reported with PureTech Health LLC
Section 16 reporting ended · disclosed 2024-07-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-07-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-07-02 · Other · Disposed 12,527,477 · Balance 0 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent"), and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"). Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person was converted into the Offer Price. F2: PureTech Health LLC is the record holder of all of the securities reported in this Form 4. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech Health LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent"), and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"). Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person was converted into the Offer Price.
F2: PureTech Health LLC is the record holder of all of the securities reported in this Form 4. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech Health LLC.
Seaport Therapeutics, Inc.
Report date May 04, 2026 · Filed May 06, 2026
Jointly reported with PureTech LYT, Inc.
Section 16 reporting ended · disclosed 2026-05-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 16,685,013 |
Last balance in matching sequence
After 2026-05-04 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2026-05-04 · Conversion · Acquired 12,736,014 · Balance 13,038,493 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Row 2 · 2026-05-04 · Conversion · Acquired 2,681,265 · Balance 15,719,758 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Row 3 · 2026-05-04 · Conversion · Acquired 965,255 · Balance 16,685,013 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-04 · Conversion · Disposed 40,000,000 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-04 · Conversion · Disposed 8,421,052 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2026-05-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-04 · Conversion · Disposed 3,031,578 · Balance 0 F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date.
F2: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries B Preferred Stock · Derivative | 3,031,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 6 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 965,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries A-2 Preferred Stock · Derivative | 8,421,052 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 5 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,681,265 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionSeries A-1 Preferred Stock · Derivative | 40,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · derivative · entry 4 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 12,736,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 965,255 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 3 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,685,013 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 2,681,265 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 2 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 15,719,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| May 04, 2026 Filed May 6, 2026 23:38 UTC | Seaport Therapeutics, Inc. SPTX · Entity 4799 | ConversionCommon Stock | 12,736,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-209701 · ownership.xml · nonDerivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech LYT, Inc. · CIK 0002131815 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,038,493 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A-1, Series A-2 and Series B Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-for-3.1407 basis at the option of the holder, and automatically converted upon the closing of the Issuer's initial public offering without payment of further consideration. The Preferred Stock had no expiration date. F2 · ownership.nature: PureTech LYT, Inc. is the record holder of all of the securities reported in this Form 4. PureTech Health LLC is the sole owner of PureTech LYT, Inc. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech LYT, Inc. and PureTech Health LLC. Read SEC document |
| July 02, 2024 Filed Jul 8, 2024 19:42 UTC | Akili, Inc. AKLI · Entity 89130 | OtherCommon Stock | 12,527,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-082232 · ownership.xml · nonDerivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent"), and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"). Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Person was converted into the Offer Price. F2 · ownership.nature: PureTech Health LLC is the record holder of all of the securities reported in this Form 4. PureTech Health plc is the sole member of PureTech Health LLC, and has the power to direct the voting and disposition of securities held by PureTech Health LLC. Read SEC document |
| September 20, 2023 Filed Sep 21, 2023 16:30 UTC | GELESIS HOLDINGS, INC. GLSH · Entity 109516 | PurchaseConvertible Note · Derivative | Not disclosed | $1,500,000.00 Strike: $0.05 | $1,500,000.00 |
DisclosureSEC source: 0000950170-23-049198 · ownership.xml · derivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 30,364,372 shares Expires 2024-03-31 Read SEC document |
| June 12, 2023 Filed Jun 14, 2023 16:30 UTC | GELESIS HOLDINGS, INC. GLSH · Entity 109516 | PurchaseConvertible Note · Derivative | Not disclosed | $3,000,000.00 Strike: $0.01 | $3,000,000.00 |
DisclosureSEC source: 0000899243-23-015533 · doc4.xml · derivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 223,880,597 shares Expires 2023-07-31 Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:30 UTC | GELESIS HOLDINGS, INC. GLHS · Entity 109516 | PurchaseWarrants · Derivative | 43,133,803 | Not disclosed Strike: $0.01 | Not disclosed |
DisclosureSEC source: 0000899243-23-014169 · doc4.xml · derivative · entry 2 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: 43,133,803 Underlying: Common Stock · 43,133,803 shares Expires 2028-05-26 F1 · price: The warrants were issued in connection with the purchase of the convertible note purchases reported herein. Read SEC document |
| May 26, 2023 Filed May 31, 2023 17:30 UTC | GELESIS HOLDINGS, INC. GLHS · Entity 109516 | PurchaseConvertible Note · Derivative | Not disclosed | $350,000.00 Strike: $0.01 | $350,000.00 |
DisclosureSEC source: 0000899243-23-014169 · doc4.xml · derivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: Not disclosed Underlying: Common Stock · 24,647,887 shares Expires 2023-07-31 Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:30 UTC | GELESIS HOLDINGS, INC. NYSE: GLS · Entity 109516 | PurchaseWarrants · Derivative | 192,307,692 | Not disclosed Strike: $0.02 | Not disclosed |
DisclosureSEC source: 0000899243-23-012087 · doc4.xml · derivative · entry 4 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: 192,307,692 Underlying: Common Stock · 192,307,692 shares Expires 2028-05-01 F3 · price: The warrants were issued in connection with the purchase of the convertible note purchases reported herein Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:30 UTC | GELESIS HOLDINGS, INC. NYSE: GLS · Entity 109516 | PurchaseWarrants · Derivative | 23,688,047 | Not disclosed Strike: $0.27 | Not disclosed |
DisclosureSEC source: 0000899243-23-012087 · doc4.xml · derivative · entry 3 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: 23,688,047 Underlying: Common Stock · 23,688,047 shares Expires 2028-02-21 F1 · security: Pursuant to a Note and Warrant Purchase Agreement, on February 21, 2023, the Issuer issued to PureTechHealth LLC convertible notes in an aggregate principal amount of $5,000,000 as well as warrants to purchase 23,688,047 shares of common stock. At the time of issuance, both the conversion of the convertible notes and exercise of the warrants was subject to the Issuer first receiving stockholder approval for the issuance of the underlying shares of common stock. On May 1, 2023, the Issuer and the Reporting Persons amended the terms of the convertible notes and warrants to remove this restriction on conversion and exercise, respectively. F3 · price: The warrants were issued in connection with the purchase of the convertible note purchases reported herein Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:30 UTC | GELESIS HOLDINGS, INC. NYSE: GLS · Entity 109516 | PurchaseConvertible Note · Derivative | 2,000,000 | $2,000,000.00 Strike: $0.02 | $4,000,000,000,000.00 |
DisclosureSEC source: 0000899243-23-012087 · doc4.xml · derivative · entry 2 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: 2,000,000 Underlying: Common Stock · 109,890,110 shares Expires 2023-07-31 F2 · derivative.underlying_shares: The number of shares underlying the convertible notes reported herein is based on the outstanding principal amount plus accrued and unpaid interest as of April 30, 2023, and such number is subject to adjustment in accordance with the terms of the convertible notes. Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:30 UTC | GELESIS HOLDINGS, INC. NYSE: GLS · Entity 109516 | PurchaseConvertible Note · Derivative | 5,000,000 | $5,000,000.00 Strike: $0.27 | $25,000,000,000,000.00 |
DisclosureSEC source: 0000899243-23-012087 · doc4.xml · derivative · entry 1 PureTech Health plc · CIK 0001782999 · 10% owner PureTech Health LLC · CIK 0001727395 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By PureTech Health LLC Disclosed balance after: 5,000,000 Underlying: Common Stock · 18,634,597 shares Expires 2023-07-31 F1 · security: Pursuant to a Note and Warrant Purchase Agreement, on February 21, 2023, the Issuer issued to PureTechHealth LLC convertible notes in an aggregate principal amount of $5,000,000 as well as warrants to purchase 23,688,047 shares of common stock. At the time of issuance, both the conversion of the convertible notes and exercise of the warrants was subject to the Issuer first receiving stockholder approval for the issuance of the underlying shares of common stock. On May 1, 2023, the Issuer and the Reporting Persons amended the terms of the convertible notes and warrants to remove this restriction on conversion and exercise, respectively. F2 · derivative.underlying_shares: The number of shares underlying the convertible notes reported herein is based on the outstanding principal amount plus accrued and unpaid interest as of April 30, 2023, and such number is subject to adjustment in accordance with the terms of the convertible notes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.